Citius Pharmaceuticals, Inc. Contracts & Agreements

Form of Investor Warrant issued on November 18, 2024 (Filed With SEC on November 18, 2024)

Form of Securities Purchase Agreement, dated as of November 15, 2024, by and among Citius Pharmaceuticals, Inc. and the investors signatory thereto (Filed With SEC on November 18, 2024)

Amended and Restated Shared Services Agreement, dated August 12, 2024, between Citius Pharmaceuticals, Inc. and Citius Oncology, Inc (Filed With SEC on August 16, 2024)

Amended and Restated Registration Rights Agreement, dated as of August 12, 2024 by and between Citius Oncology, Inc. and the signatories thereto (Filed With SEC on August 16, 2024)

Side Letter Agreement, dated August 12, 2024, by and by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc (Filed With SEC on August 16, 2024)

Promissory note, dated August 16, 2024, issued to Citius Pharmaceuticals, Inc. by Citius Oncology, Inc (Filed With SEC on August 16, 2024)

At the Market Offering Agreement, dated as of August 12, 2024, between Citius Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on August 12, 2024)

Form of Investor Warrant issued on April 30, 2024 (Filed With SEC on April 30, 2024)

Form of Securities Purchase Agreement, dated as of April 25, 2024, by and among Citius Pharmaceuticals, Inc. and the investors signatory thereto (Filed With SEC on April 30, 2024)

Form of Common Stock Purchase Warrant, dated August 13, 2018, as amended August 8, 2023 (Filed With SEC on December 29, 2023)

Form of Underwriters Common Stock Purchase Warrant, dated August 13, 2018, as amended August 8, 2023 (Filed With SEC on December 29, 2023)

Agreement and Plan of Merger, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition, and TenX Merger Sub Inc (Filed With SEC on October 24, 2023)

Sponsor Support Agreement, dated as of October 23, 2023, by and among 10XYZ Holdings LP, TenX Keane Acquisition, Citius Pharmaceuticals, Inc. and Citius Oncology, Inc (Filed With SEC on October 24, 2023)

Form of Amended and Restated Registration Rights Agreement (Filed With SEC on October 24, 2023)

Form of Amended and Restated Shared Services Agreement (Filed With SEC on October 24, 2023)

Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc (Filed With SEC on May 12, 2023)

Form of Warrant issued May 8, 2023 (Filed With SEC on May 8, 2023)

Form of Placement Agent Warrant issued May 8, 2023 (Filed With SEC on May 8, 2023)

Form of Securities Purchase Agreement, dated May 3, 2023, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto (Filed With SEC on May 8, 2023)

Description of Common Stock (Filed With SEC on December 22, 2022)

Amended and Restated Employment Agreement between Myron Holubiak and Citius Pharmaceuticals, Inc., dated April 12, 2022 and effective May 1, 2022 (Filed With SEC on May 12, 2022)

Form of Notice of Stock Option Grant and Stock Option Award Agreement (Filed With SEC on December 15, 2021)

Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddys Laboratories S.A. and Citius Pharmaceuticals, Inc (Filed With SEC on December 15, 2021)

Amended and Restated License, Development and Commercialization Agreement, dated as of February 26, 2018, between Eisai, Ltd. and Dr. Reddys Laboratories S.A (Filed With SEC on December 15, 2021)

Amendment to Amended and Restated License, Development and Commercialization Agreement, dated as of August 9, 2018, between Eisai, Ltd. and Dr. Reddys Laboratories S.A (Filed With SEC on December 15, 2021)

Amendment No. 2 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 31, 2021, between Eisai, Ltd. and Dr. Reddys Laboratories S.A (Filed With SEC on December 15, 2021)

Form of investor warrant issued February 19, 2021 (Filed With SEC on February 19, 2021)

Form of placement agent warrant issued February 19, 2021 (Filed With SEC on February 19, 2021)

Form of Securities Purchase Agreement, dated February 16, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto (Filed With SEC on February 19, 2021)

Form of investor warrant issued January 27, 2021 (Filed With SEC on January 27, 2021)

Form of placement agent warrant issued January 27, 2021 (Filed With SEC on January 27, 2021)

Form of Registration Rights Agreement, dated January 24, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto (Filed With SEC on January 27, 2021)

Form of Securities Purchase Agreement, dated January 24, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto (Filed With SEC on January 27, 2021)

Engagement letter, dated January 23, 2021, between Citius Pharmaceuticals, Inc. and H. C. Wainwright & Co., LLC (Filed With SEC on January 27, 2021)

License Agreement, dated October 6, 2020, between NoveCite, Inc. and Novellus Therapeutics, Limited (Filed With SEC on December 16, 2020)

Employment Agreement, effective as of July 14, 2020, between Citius Pharmaceuticals, Inc. and Myron Czuczman (Filed With SEC on August 14, 2020)

Amended and Restated Underwriting Agreement between Citius Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC, dated as of August 5, 2020 (Filed With SEC on August 10, 2020)

Form of Underwriter Warrant (Filed With SEC on August 10, 2020)

Form of investor warrant issued May 18, 2020 (Filed With SEC on May 18, 2020)

Form of placement agent warrant issued May 18, 2020 (Filed With SEC on May 18, 2020)

Form of Securities Purchase Agreement, dated May 14, 2020, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto (Filed With SEC on May 18, 2020)

Engagement letter, dated February 14, 2020, between Citius Pharmaceuticals, Inc. and H. C. Wainwright & Co., LLC (Filed With SEC on May 18, 2020)

Form of Investor Warrant issued on February 19, 2020 (Filed With SEC on February 19, 2020)

Form of Placement Agent Warrant issued on February 19, 2020 (Filed With SEC on February 19, 2020)

Form of Warrant Exercise Agreement, dated February 14, 2020, by and between Citius Pharmaceuticals, Inc. and the investor signatory thereto (Filed With SEC on February 19, 2020)

Form of Notice of Stock Option Grant and Stock Option Award Agreement (Filed With SEC on February 13, 2020)

Underwriting Agreement, dated as of September 25, 2019, by and between Citius Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on September 27, 2019)

Form of Common Stock Purchase Warrant issued on September 27, 2019 (Filed With SEC on September 27, 2019)

Form of Pre-Funded Common Stock Purchase Warrant issued on September 27, 2019 (Filed With SEC on September 27, 2019)

Form of Underwriters Common Stock Purchase Warrant issued on September 27, 2019 (Filed With SEC on September 27, 2019)

Form of Underwriting Agreement (Filed With SEC on September 20, 2019)

Form of Common Stock Purchase Warrant (Filed With SEC on September 20, 2019)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on September 20, 2019)

Form of Underwriters Common Stock Purchase Warrant (Filed With SEC on September 20, 2019)

Form of investor warrant (Filed With SEC on April 3, 2019)

Form of placement agent warrant (Filed With SEC on April 3, 2019)

Form of Securities Purchase Agreement, dated April 1, 2019, by and between Citius Pharmaceuticals, Inc. and the purchasers named therein (Filed With SEC on April 3, 2019)

Engagement letter, dated March 22, 2019, between Citius Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on April 3, 2019)

Patent and Technology License Agreement, dated January 2, 2019, between the Board of Regents of the University of Texas System on behalf of the University of Texas M. D. Anderson... (Filed With SEC on February 14, 2019)

First Amendment, dated October 15, 2015, to Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron... (Filed With SEC on February 14, 2019)

Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc (Filed With SEC on February 14, 2019)

Amended and Restated Employment Agreement between Leonard Mazur and Citius Pharmaceuticals, Inc., dated October 19, 2017 (Filed With SEC on December 11, 2018)

Underwriting Agreement, dated as of August 9, 2018, by and between Citius Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on August 13, 2018)

Form of Common Stock Purchase Warrant issued on August 13, 2018 (Filed With SEC on August 13, 2018)

Form of Pre-Funded Common Stock Purchase Warrant issued on August 13, 2018 (Filed With SEC on August 13, 2018)

Form of Underwriters Common Stock Purchase Warrant issued on August 13, 2018 (Filed With SEC on August 13, 2018)

Form of Underwriting Agreement (Filed With SEC on August 6, 2018)

Form of Common Stock Purchase Warrant (Filed With SEC on August 6, 2018)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on August 6, 2018)

Form of Underwriters Common Stock Purchase Warrant (Filed With SEC on August 6, 2018)

Form of investor warrant (Filed With SEC on March 29, 2018)

Form of placement agent warrant (Filed With SEC on March 29, 2018)

Form of Securities Purchase Agreement, dated March 28, 2018, by and between Citius Pharmaceuticals, Inc. and the purchasers named therein (Filed With SEC on March 29, 2018)

Engagement letter, dated March 28, 2018, between Citius Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on March 29, 2018)

Release Agreement, dated November 7, 2017, between Citius Pharmaceuticals, Inc., and Aegis Capital Corp (Filed With SEC on February 14, 2018)

Citius Pharmaceuticals, Inc. 2018 Omnibus Stock Incentive Plan (Filed With SEC on February 14, 2018)

Form of investor warrant (Filed With SEC on December 19, 2017)

Form of placement agent warrant (Filed With SEC on December 19, 2017)

Form of Securities Purchase Agreement, dated December 15, 2017, by and between Citius Pharmaceuticals, Inc. and the purchasers named therein (Filed With SEC on December 19, 2017)

Engagement letter, dated November 10, 2017, between Citius Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on December 19, 2017)

Employment Agreement dated November 27, 2017 between Jaime Bartushak and Citius Pharmaceuticals, Inc (Filed With SEC on December 1, 2017)

Underwriting Agreement dated August 3, 2017 between Citius Pharmaceuticals, Inc. and Aegis Capital Corp (Filed With SEC on August 4, 2017)

Warrant Agent Agreement dated August 3, 2017 between Citius Pharmaceuticals, Inc. and VStock Transfer, LLC (Filed With SEC on August 4, 2017)

Form of Representatives Warrant (Filed With SEC on August 4, 2017)

Form of Warrant Agreement (Filed With SEC on July 28, 2017)

Form of Warrant Agreement (Filed With SEC on July 24, 2017)

Underwriting Agreement with Aegis Capital Corp (Filed With SEC on July 13, 2017)

Form of Warrant Agreement (Filed With SEC on July 13, 2017)

Form of Representatives Warrant (Filed With SEC on July 13, 2017)

Release Agreement by and between Citius Pharmaceuticals, Inc. and Garden State Securities, Inc. dated June 7, 2017 (Filed With SEC on June 13, 2017)

Form of Release Agreement by and between Citius Pharmaceuticals, Inc. and each investor dated June 8, 2017 (Filed With SEC on June 13, 2017)

Future Advance Convertible Promissory Note dated May 10, 2017 between Leonard Mazur and the Company (Filed With SEC on May 15, 2017)

Conversion Agreement dated May 10, 2017 between Leonard Mazur and the Company (Filed With SEC on May 15, 2017)

Amended and Restated Demand Convertible Promissory Note dated May 10, 2017 between Leonard Mazur and the Company (Filed With SEC on May 15, 2017)

Form of Common Stock Purchase Warrant (Filed With SEC on May 15, 2017)

Form of Unit Purchase Agreement (Filed With SEC on May 15, 2017)

Placement Agency Agreement dated September 27, 2016 between Garden State Securities, Inc. and the Company (Filed With SEC on May 15, 2017)

Amendment to Placement Agency Agreement dated November 23, 2016 between Garden State Securities, Inc. and the Company (Filed With SEC on May 15, 2017)

Second Amendment to the Patent and Technology License Agreement dated March 20, 2017 between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc (Filed With SEC on May 15, 2017)

DEMAND NOTE (Filed With SEC on October 26, 2016)

DEMAND PROMISSORY NOTE (Filed With SEC on October 12, 2016)

CITIUS PHARMACEUTICALS, INC. 2014 STOCK INCENTIVE PLAN (effective September 12, 2014, subject to stockholder approval) (Filed With SEC on August 15, 2016)

CITIUS PHARMACEUTICALS, INC. 2014 STOCK INCENTIVE PLAN Nonqualified Stock Option Agreement (Filed With SEC on August 15, 2016)

AGREEMENT AND PLAN OF MERGER BY AND AMONG CITIUS PHARMACEUTICALS, INC., CITIUS LMB ACQUSITION CORP. AND LEONARD-MERON BIOSCIENCES, INC. Dated as of March 30, 2016 (Filed With SEC on April 5, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on April 5, 2016)

STOCK SUBSCRIPTION AGREEMENT (Filed With SEC on April 5, 2016)

VOTING AGREEMENT (Filed With SEC on April 5, 2016)

Placement Agent's Unit Warrants (Filed With SEC on December 29, 2015)

AMENDMENT AND COORDINATION AGREEMENT (Filed With SEC on November 4, 2015)

COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on November 4, 2015)

CONSULTANT SERVICES AGREEMENT (Filed With SEC on November 4, 2015)

EXCLUSIVE LICENSE AGREEMENT Prenzamax, LLC and Citius Pharmaceuticals, LLC 1 EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on November 4, 2015)

QUOTATION Product Development and Pilot Lot Manufacturing Proposal Version 01 Citius Pharmaceuticals LLC (Referred to as "Customer") (Filed With SEC on November 4, 2015)

SUPPLY AGREEMENT (Filed With SEC on November 4, 2015)

TECHNICAL & QUALITY AGREEMENT (Filed With SEC on November 4, 2015)

AMENDMENT AND COORDINATION AGREEMENT (Filed With SEC on October 16, 2015)

COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on October 16, 2015)

CONSULTANT SERVICES AGREEMENT (Filed With SEC on October 16, 2015)

EXCLUSIVE LICENSE AGREEMENT Prenzamax, LLC and Citius Pharmaceuticals, LLC 1 EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on October 16, 2015)

QUOTATION Product Development and Pilot Lot Manufacturing Proposal Version 01 Citius Pharmaceuticals LLC (Referred to as Customer) (Filed With SEC on October 16, 2015)

SUPPLY AGREEMENT (Filed With SEC on October 16, 2015)

TECHNICAL & QUALITY AGREEMENT (Filed With SEC on October 16, 2015)

INTRODUCTION (Filed With SEC on September 18, 2014)

SUBSCRIPTION AGREEMENT (Filed With SEC on September 18, 2014)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on September 18, 2014)

EffectiveDate: September 12, 2014Void After: September 12, 2019 CITIUS PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on September 18, 2014)

PROMISSORY NOTE (PAYABLE ON DEMAND) (Filed With SEC on July 7, 2011)

PROMISSORY NOTE (PAYABLE ON DEMAND) $8,195.00March 31, 2011 (Filed With SEC on June 23, 2011)

Category

Industry

Companies

Contracts

Citius Pharmaceuticals, Inc. Contracts & Agreements